NCT04087525View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

November 27, 2018

Study Completion Date

November 27, 2018

Conditions
Health, Subjective
Interventions
DRUG

HIP1701

Vildagliptin

DRUG

HGP1809

Vildagliptin

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04087525 - A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects | Biotech Hunter | Biotech Hunter